No. 55Articles
On this page

All reading for this session

· No. 055

Market events

SELLAS (SLS) reports longer survival in its Phase 3 REGAL trial

SELLAS reported median survival of 24.0 versus 14.7 months in its Phase 3 REGAL trial. See who was studied, the FDA filing target and funding context.

Abstract bar field showing the size of each five-minute move during the session, without labels.
Abstract bar field showing the size of each five-minute move during the session, without labels.

On Nov. 17, 2026, SELLAS Life Sciences (SLS) reported that its randomized Phase 3 REGAL trial met its primary endpoint of overall survival. The study evaluated galinpepimut-S (GPS), an investigational cancer immunotherapy, as maintenance treatment for a specific group of patients with acute myeloid leukemia (AML). Nov. 17 Form 8-K and Exhibit 99.1

What the survival numbers show

SELLAS reported median overall survival of 24.0 months with GPS versus 14.7 months with investigator-selected best available treatment. The median difference was 9.3 months. The reported hazard ratio was 0.59, with a two-sided p value of 0.035. The company said it ran the prespecified primary analysis after the trial reached 80 deaths. SELLAS results announcement

The 9.3 months compare the medians of the two groups. An individual's outcome can vary. The hazard ratio corresponds to an estimated 41% lower instantaneous hazard of death during follow-up. An absolute survival difference would instead compare the share of patients still alive in each arm at a specified time.

Who was studied

REGAL randomly assigned 126 patients 1:1 in an open-label trial. Participants had achieved a second or later complete remission, or the corresponding remission with insufficient platelet recovery, after second-line or later salvage treatment. They were ineligible for or unable to undergo an allogeneic stem cell transplant. GPS was given alone as maintenance therapy. Investigators chose the comparator for each control patient from options that included observation and low-intensity treatments. The results apply to maintenance in this defined AML setting. Trial design in the company disclosure

What the full analysis can clarify

The company reported no new safety signals. Treatment-related events were predominantly mild to moderate, with local injection-site reactions the most common. It also reported that few participants later underwent transplant, with similar numbers in the two arms. The detailed results can show how the survival curves separate over time, how precisely the hazard ratio was estimated, and how severe adverse events and treatment discontinuations compare. SELLAS says it is still analyzing secondary endpoints and other prespecified results. Form 8-K and results exhibit

The first half of 2027 is a company filing target

SELLAS plans to meet with the FDA to discuss an accelerated filing strategy and is preparing for a Biologics License Application (BLA) submission in the first half of 2027. That is the company's target for submitting the application. Filing, FDA acceptance for review and a decision are separate milestones. Eligibility for expedited review and the eventual label remain open questions. Company regulatory plan

Cash and dilution

SELLAS held $134.7 million in cash and cash equivalents at Sept. 30, 2026, and used $22.4 million in operating cash over the first nine months of the year. Management expects cash to cover its current operating plan for at least 12 months from issuance of the financial statements. That estimate depends on the current plan. Manufacturing, filing and any launch could change the financing needs. The same 10-Q says SELLAS had yet to sell shares through its $150 million at-the-market equity program. The program gives the company a way to raise cash by issuing shares, with dilution if it uses that capacity. Third-quarter Form 10-Q

This article explains common concepts; examples are not trading recommendations.